{
    "2019-06-06": [
        [
            {
                "time": "2018-05-15",
                "original_text": "Incyte Begins Phase III Study for Treatment of Duct Cancer",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Phase III",
                        "Treatment",
                        "Duct Cancer"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-03-20",
                "original_text": "Alnylam Completes Rolling NDA Submission to FDA for Givosiran",
                "features": {
                    "keywords": [
                        "Alnylam",
                        "NDA",
                        "FDA",
                        "Givosiran"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-06-03",
                "original_text": "Was ASCO Quieter for Big Drug/Biotech Stocks This Year?",
                "features": {
                    "keywords": [
                        "ASCO",
                        "Drug",
                        "Biotech",
                        "Stocks"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-11-14",
                "original_text": "The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",
                "features": {
                    "keywords": [
                        "Takeda",
                        "Amyloidosis",
                        "Drug Trial",
                        "Chiasma",
                        "CEO Appointment",
                        "Orchard",
                        "Prices Offering"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}